Fennec Pharmaceuticals Inc.
FENC
Health Care
2
exclusion reasons
1 theme
This page is part of our public exclusion list — a transparency tool that shows which companies we screen out and why. It is not investment advice, and it is not an accusation. But it is subject to change as our understanding of the facts evolves.
Fennec Pharmaceuticals is a biotechnology company whose sole marketed product, PEDMARK, is a pediatric oncology drug designed to prevent hearing loss caused by cisplatin chemotherapy. The drug's development and regulatory approval process required animal testing as mandated by the U.S. Food and Drug Administration. The company's 2022 FDA New Drug Application multidisciplinary review documents reference the standard nonclinical toxicology studies, which are conducted in animal models, as part of the drug approval package. As a pharmaceutical company developing new chemical entities, Fennec's business model is inherently reliant on animal testing for regulatory compliance and product development.
Fennec Pharmaceuticals Inc. is a biopharmaceutical company focused on the development of PEDMARK (sodium thiosulfate), an FDA-approved drug to reduce the risk of ototoxicity associated with cisplatin chemotherapy in pediatric patients. The company acknowledges in its public disclosures that its development process relies on animal testing. Its 2024 Form 10-K states: "Much of our testing has been conducted on animals or on human cells in the laboratory." As a clinical-stage biopharma company seeking regulatory approval for novel therapeutics, Fennec's business model inherently involves commissioning and submitting animal studies to the U.S. Food and Drug Administration as part of its product development and compliance process.
Research Sources
1 organization
Related Exclusions
Wondering what we do invest in?
The Naughty List
A digest of changes to our exclusion list — new additions, removals, and the evidence behind them. We review the list continuously as new evidence surfaces.
Companies appear on our exclusion list based on our investment judgment — not because they've done anything illegal. This is a difference of values and opinion, not an accusation of wrongdoing. Exclusion does not constitute a recommendation against investing in any company, and absence from the list does not constitute a recommendation to invest.
This information is provided for educational and transparency purposes only and should not be relied upon as investment advice. Data is drawn from independent watchdogs, NGOs, government registries, and Ethical Capital's ongoing research — see Research Sources for the full list.
Ethical Capital LLC is a state-registered investment adviser in Utah (CRD #316032). Registration does not imply a certain level of skill or training.